Comparing Intramuscular Fentanyl and Ketorolac With Nerve of Arnold (NOA) Block for Bilateral Myringotomy

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age6-6
SponsorUniversity of South Alabama

About this trial

Background: Bilateral myringotomy with tympanostomy tube (BMT) placement is one of the most common pediatric surgical procedures. Despite its brief duration, many children experience significant postoperative pain. Current standard care typically involves intramuscular (IM) administration of an opioid (fentanyl) combined with a non-steroidal anti-inflammatory drug (ketorolac). While this multimodal approach provides adequate pain control for approximately 75% of children, it is associated with opioid-related side effects including respiratory depression, nausea, vomiting, and sedation. Additionally, nearly one-quarter of children still experience moderate-to-severe pain despite this regimen.

The Nerve of Arnold block is a regional anesthesia technique that involves injection of local anesthetic near the auricular branch of the vagus nerve, which provides sensory innervation to the external auditory canal and tympanic membrane. This technique offers the potential for targeted, opioid-sparing analgesia with extended duration and minimal systemic side effects. However, high-quality evidence comparing this regional technique to standard systemic analgesia in pediatric patients is lacking.

Study Objective: This study aims to determine whether the Nerve of Arnold block is non-inferior to the standard combination of IM fentanyl and IM ketorolac in controlling postoperative pain in children undergoing BMT placement.

Study Design: This is a prospective, randomized, double-blind, non-inferiority trial. Three hundred children aged 6 months to 6 years scheduled for bilateral myringotomy with tympanostomy tube placement will be randomized 1:1 to receive either: (1) Standard care: IM fentanyl (1-2 mcg/kg) plus IM ketorolac (0.5 mg/kg) with sham Nerve of Arnold block, or (2) Intervention: Bilateral Nerve of Arnold block with bupivacaine 0.25% plus sham IM injections. Both patients and outcome assessors will be blinded to treatment assignments.

Primary Outcome: The proportion of patients experiencing moderate-to-severe pain (Face, Legs, Activity, Cry, Consolability \[FLACC\] scale score ≥4) in the Post-Anesthesia Care Unit (PACU). Non-inferiority will be declared if the upper bound of the 95% confidence interval for the difference in proportions is less than 10 percentage points.

Secondary Outcomes: Secondary outcomes include mean and maximum FLACC scores, rescue analgesic requirements, respiratory depression, postoperative nausea and vomiting, PACU length of stay, parent satisfaction, and pain at 24 hours postoperatively.

Clinical Significance: If the Nerve of Arnold block is shown to be non-inferior to standard care, it could provide a valuable opioid-sparing alternative for postoperative pain management in pediatric ear surgery, potentially reducing opioid-related adverse events while maintaining effective analgesia. This would be particularly beneficial for patients with contraindications to opioids or NSAIDs and aligns with national efforts to reduce opioid exposure in pediatric populations.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Allergy to study medications (fentanyl, ketorolac, bupivacaine)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Fentanyl

    Drug

    Intramuscular fentanyl 2 mcg/kg (maximum 100 mcg) administered after induction of anesthesia

  • Ketorolac

    Drug

    Intramuscular ketorolac 0.5 mg/kg (maximum 30 mg) administered after induction of anesthesia

  • Nerve of Arnold Block

    Procedure/Surgery

    Bilateral Nerve of Arnold block with bupivacaine 0.25%, 0.2 mL per side (total 0.4 mL), administered after induction of anesthesia

  • Sham Intramuscular Injection

    Procedure/Surgery

    sham intramuscular injections with normal saline to maintain blinding

  • Sham Nerve of Arnold Block

    Procedure/Surgery

    Bilateral sham Nerve of Arnold block with normal saline 0.2 mL per side to maintain blinding

  • Dexmedetomidine

    Drug

    Dexmedetomidine 5 mcg per side (10 mcg total) added to bupivacaine solution for Nerve of Arnold block as adjuvant to prolong block duration

  • Bupivacaine

    Drug

    Bupivacaine 0.25% with epinephrine 1:200,000, 0.2 mL per side (total 0.4 mL, maximum 2.5 mg/kg) for bilateral Nerve of Arnold block

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: IM Arm standard CareActive comparator 3 interventions
Group B: Nerve block armExperimental treatment 4 interventions

Trial outcomes

Primary outcomes

1

Number of Participants with Moderate-to-Severe Pain (FLACC Score ≥4) During PACU Stay

Number of participants experiencing at least one FLACC (Face, Legs, Activity, Cry, Consolability) scale score of 4 or greater during Post-Anesthesia Care Unit stay. FLACC is a validated behavioral pain assessment tool scored 0-10, with scores ≥4 indicating moderate-to-severe pain. FLACC scores assessed every 15 minutes during PACU stay.

Time frame
From PACU admission to PACU discharge, up to 1 hour

Secondary outcomes

1

Highest FLACC Pain Score During PACU Stay

Time frame
From PACU admission to meeting PACU discharge criteria
2

Number of Participants Requiring Rescue Analgesia

Number of participants requiring at least one dose of rescue analgesic medication for FLACC score ≥4

Time frame
From PACU admission to meeting PACU discharge criteria
3

Number of Participants with Respiratory Depression

Number of participants with oxygen saturation below 95% requiring intervention (supplemental oxygen, stimulation, or airway repositioning)

Time frame
From PACU admission to meeting PACU discharge criteria
4

Number of Participants with Postoperative Nausea and Vomiting

Number of participants experiencing at least one episode of nausea or vomiting

Time frame
From PACU admission to meeting PACU discharge criteria

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: